Figure 4.

μ-CT data confirming that CMC 2.24 significantly inhibits alveolar bone resorption in the in vivo model of LPS-induced periodontal disease. Rats received either 2% carboxymethylcellulose vehicle or 30 mg/Kg of CMC 2.24 by oral intubation daily for 2 weeks. Contralateral LPS (3 μL, 30 μg) or PBS (3 μL) vehicle injections were performed 3 times/week for 14 days at the palatal aspect of first molars (see Figure 1). The bar graph presents the results of the μ-CT analysis as the change in the bone volume fraction (BVF) in the standardized ROI (bidimensionally shown as a red box in the representative image of the control) in comparison to vehicle-treated/PBS-injected samples (BVF in these samples was set to 100% since these were assumed to present no inflammatory bone resorption). Bars indicate average and standard deviations.  *Significant difference in comparison to PBS-injected/vehicle-treated control. Differences between experimental conditions are indicated by the brackets and ∗ (unpaired t-test for independent samples with Welch's correction for unequal variances). Images in (b) show three-dimensional rendering of the mineralized tissues in representative samples.